Guiding Practices For Patient-Centered Value Assessment
How do we measure the value of a medical intervention, its benefits to patients, and the associated costs to patients, payers and society as a whole? NPC outlines 28 specific elements to help guide meaningful value assessment.
NPC Testifies at FDA Meeting on Manufacturer Communications
NPC Vice President for Comparative Effectiveness Research Jennifer Graff, PharmD, testified before the Food and Drug Administration on "Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products."
Amgen’s Dr. Joshua Ofman Elected Chairman of NPC’s Board of Directors
The National Pharmaceutical Council Board of Directors elected Joshua Ofman, MD, MSHS, Senior Vice President of Global Value, Access & Policy, Amgen, as its 2016-2017 Chairman. Dr. Ofman has served on NPC’s Board since 2012, most recently as Vice Chairman.